Inflammation is a major contributor to atherosclerosis by its effects on arterial wall biology and lipoprotein metabolism. Interleukin-10 (IL-10) is an anti-inflammatory cytokine that may modulate the atherosclerotic disease process. We investigated the effects of adeno-associated virus (AAV) vector-mediated gene transfer of IL-10 on atherogenesis in apolipoprotein E (ApoE)-deficient mice. A murine myoblast cell line, C2C12, transduced with AAV encoding murine IL-10 (AAV2-mIL10) secreted substantial amounts of IL-10 into conditioned medium. The production of monocyte chemoattractant protein-1 (MCP-1) by the murine macrophage cell line, J774, was significantly inhibited by conditioned medium from AAV2-mIL10-transduced C2C12 cells. ApoE-deficient mice were injected with AAV5-mIL10 into their anterior tibial muscle at 8 weeks of age. The expression of MCP-1 in the vascular wall of the ascending aorta and serum MCP-1 concentration were decreased in AAV5-mIL10-transduced mice compared with AAV5-LacZ-transduced mice. Oil red-O staining of the ascending aorta revealed that IL-10 gene transfer resulted in a 31% reduction in plaque surface area. Serum cholesterol concentrations were also significantly reduced in AAV5-mIL10-transduced mice. To understand the cholesterol-lowering mechanism of IL-10, we measured the cellular cholesterol level in HepG2 cells, resulting in its significant decrease by the addition of IL-10 in a dosedependent manner. Furthermore, IL-10 suppressed HMGCoA reductase expression in the HepG2 cells. These observations suggest that intramuscular injection of AAV5-mIL10 into ApoE-deficient mice inhibits atherogenesis through anti-inflammatory and cholesterol-lowering effects.
Introduction
The inflammatory reaction involves complex interactions between inflammatory cells (lymphocytes and macrophages) and vascular endothelial and smooth muscle cells. The disturbance of vascular wall integrity and homeostasis by inflammation is thought to be a major contributor to atherosclerosis. Therefore, an anti-inflammatory strategy may be a promising approach to prevent and treat atherosclerotic disease. Another critical feature of atherogenesis is lipid accumulation. Several largescale clinical trials have demonstrated that lipid reduction therapy involving HMG-CoA reductase inhibitor (statin) is useful for atherosclerotic disorders, such as ischemic heart disease. 1, 2 Recent studies have indicated that statins have pleiotropic effects on the atherogenic process, including an anti-inflammatory effect. 3 On the other hand, proinflammatory cytokines, such as tumor necrosis factor (TNF)-a, interleukin (IL)-1, and IL-6, have profound effects on lipid metabolism. 4 These findings suggest that there are complex interactions between inflammation and lipid metabolism.
IL-10, which is secreted by a wide variety of cells such as lymphocytes and macrophages, is a key inhibitor in a number of inflammatory responses, 5 including the production of proinflammatory cytokines and chemokines and the expression of endothelial adhesion molecules. IL-10 expression has been identified in early and advanced atherosclerotic plaques 6, 7 and is thought to have potential antiatherogenic effects. Indeed, recent studies have shown that IL-10-transgenic mice fed a high-fat diet exhibit a decrease in atherogenesis. 8 Conversely, IL-10-deficient mice were found to suffer from more severe atherosclerosis, and the atherogenic tendency of these mice was ameliorated by the plasmid-mediated introduction of IL-10.
9 IL-10 is thought to have a protective role in human atherosclerotic disease as well. 10, 11 Despite the tremendous interest in the effects of cytokines on inflammation and lipoprotein metabolism, there have been few studies that have examined the influence of IL-10 on these processes in vivo. 12, 13 As atherogenesis is a chronic process, the long-term expression of IL-10 is required in order to assess its effects on this disease. In this study, we have used adenoassociated virus (AAV) vectors for IL-10 gene transfer to investigate the antiatherosclerotic effects of IL-10 in vivo, because these vectors can transduce skeletal muscle and permit the sustained expression and systemic delivery of therapeutic proteins following a single intramuscular administration. 14 
Results

IL-10 expression in C2C12 cells
We first verified the integrity of our vectors in vitro. Differentiated C2C12 cells, murine myoblasts, were transduced with AAV encoding murine IL-10 (AAV2-mIL10) at various dosages and cultured for 48 h. The concentration of IL-10 in the conditioned medium was found to increase in a vector dose-dependent manner ( Figure 1a ). Western blot analysis demonstrated the presence of an 18-kDa product, the size expected for murine IL-10, in the conditioned medium of AAV2-mIL10-transduced C2C12 cells, but not in the conditioned medium of AAV2-LacZ-transduced cells (Figure 1b) .
To evaluate the biological activity of secreted IL-10, we examined the influence of conditioned medium from AAV2-mIL10-transduced C2C12 cells on cytokine production by J774 cells, murine macrophages. As shown in Figure 1c , treatment with lipopolysaccharide (LPS) increased the production of the cytokines, IL-6, TNF-a, and monocyte chemoattractant protein-1 (MCP-1), from J774 cells. These increases were significantly inhibited by the addition of conditioned medium from AAV2-mIL10-transduced C2C12 cells, and the production of these cytokines was completely restored in the presence of anti-mIL-10 antibody (1 mg/ml). Unstimulated J774 cells did not exhibit any change in cytokine expression when exposed to the conditioned medium.
IL-10 expression in apolipoprotein E-deficient mice
We next injected AAV2-mIL10 and AAV5-mIL10 into the anterior tibial muscle of apolipoprotein E (ApoE)-deficient mice. The serum concentration of IL-10 increased in a vector dose-dependent manner, and the efficacy of transduction was higher in AAV5-mIL10-treated mice than in AAV2-mIL10-treated mice at the same vector dose (1 Â 10 13 genome copies/body) ( Figure  2 ). When 1 Â 10 12 genome copies/body of AAV5-mIL10 were injected, the serum IL-10 levels (1.2-4.9 ng/ml) were maintained at a higher than physiological range (up to 160 pg/ml) for 8 weeks. Moreover, the serum IL-10 levels at 14 months were 398.37146.6 pg/ml.
Effect of IL-10 on MCP-1 expression
We then investigated the anti-inflammatory effects of IL-10 in ApoE-deficient mice by focusing on the expression of MCP-1, a potent chemokine implicated in atherogenesis. ApoE-deficient mice transduced with AAV5-mIL10 at 4 weeks old were evaluated at 8 weeks old. Few atherosclerotic lesions were detected by oil red-O staining at this time point. An immunohistochemical analysis of MCP-1 in the aortic sinus of ApoE-deficient mice revealed that MCP-1 expression was modestly suppressed in AAV5-mIL10-transduced mice, whereas it was clearly observed in the vascular wall of AAV5-LacZtransduced mice (Figure 3a) . Moreover, 8 weeks after gene transfer, the serum concentration of MCP-1 in AAV5-mIL10-transduced mice was significantly reduced compared with that in AAV5-LacZ-transduced mice (Figure 3b ).
Effects of IL-10 on atherogenesis
We evaluated the lesion area in ApoE-deficient mice fed an atherogenic diet 8 weeks after gene transfer. As shown in Figure 4 , the aortic sinus of mice transduced with AAV5-mIL10 revealed a significant decrease in oil Figure 5 shows that serum MCP-1 concentration correlates with the extent of atherosclerotic lesion formation, suggesting that a decrease in MCP-1 expression is related to a decrease in atherosclerotic lesion formation.
Effect of IL-10 on lipids
We investigated the effects of IL-10 expression on the level of serum lipids. Total cholesterol levels were significantly reduced in the AAV5-mIL10-transduced mice (9317432, 10747419 mg/dl) compared to the AAV5-LacZ-transduced mice (22127640, 18407421 mg/dl, 4 weeks and 8 weeks after gene transfer, respectively). Triglyceride level in the AAV5-IL10-transduced mice 8 weeks after gene transfer was also reduced (171.7767.3 mg/ dl) compared to that in the AAV5-LacZ-transduced mice (291.67172.4 mg/dl, Po0.05).
Nonlinear regression fitting to a sigmoidal dose curve revealed a high correlation between the serum cholesterol level and IL-10 concentration (r ¼ 0.857), with an estimated EC 50 of 5.3 ng/ml (Figure 6a ). In addition, the serum cholesterol concentration positively correlated with the atherosclerotic lesion area (r ¼ 0.728, Po0.01; Figure 6b ). IL-10 gene transfer did not affect body Antiatherogenic effect of AAV-mediated IL-10 gene transfer T Yoshioka et al weight, food intake, blood sugar levels, or blood pressure (data not shown).
To assess whether IL-10 causes changes in the lipoprotein profile of apoE-deficient mice, plasma lipoproteins were subjected to agarose gel electrophoresis. No differences in the patterns of lipoprotein expression were observed in AAV5-mIL10-transduced mice and AAV5-LacZ-transduced mice (data not shown).
To further understand the mechanism by which the serum cholesterol level is decreased in AAV5-mIL10-transduced mice, we evaluated cholesterol levels of HepG2 cells, human hepatocytes, incubated in the absence of lipoprotein. As shown in Figure 7 , the level of cholesterol in HepG2 cells was significantly decreased by the addition of IL-10 in a dose-dependent manner. The level of intracellular cholesterol was also significantly decreased by the addition of HMG-CoA reductase inhibitor, fluvastatin, to these cells. When HepG2 cells were incubated in the presence of lipoprotein, the level of cholesterol in the conditioned medium was not decreased by the addition of IL-10 (data not shown). These data suggest that IL-10 reduces de novo cholesterol synthesis, but does not stimulate cholesterol uptake by hepatocytes. Furthermore, we estimated the effect of IL-10 on the expression of HMG-CoA reductase. Interestingly, IL-10 significantly decreased mRNA levels of HMG-CoA reductase (Po0.01), while fluvastatin, enzyme inhibitor, did not alter the expression of the enzyme itself (Figure 8 ).
Discussion
IL-10, a pleiotropic cytokine produced by Th2-type T cells, B cells, monocytes, and macrophages, has potent anti-inflammatory properties. The main finding of the present study is that AAV vector-mediated IL-10 gene transfer to ApoE-deficient mice following a single intramuscular administration inhibits atherosclerotic lesion formation through the inhibition of MCP-1 expression and the reduction in the level of serum cholesterol.
Differentiated C2C12 cells transduced with AAV2-mIL10 were verified by Western blot analysis and enzyme-linked immunosorbent assay (ELISA) to express IL-10. The biological activity of the secreted IL-10 was also confirmed. Conditioned medium from C2C12 cells transduced with AAV2-mIL10 significantly inhibited the production of IL-6, TNF-a, and MCP-1 by J774 cells in response to LPS treatment. Based on these in vitro observations, we used recombinant AAV constructs to evaluate the effects of IL-10 on atherogenesis in ApoEdeficient mice. Intramuscular injection of AAV5-mIL10 into ApoE-deficient mice resulted in long-term systemic IL-10 expression. The serum IL-10 concentration was sustained at levels higher than 398.37146.6 pg/ml (n ¼ 6) up to 14 months after gene transfer (1 Â 10 12 genome copies/body).
Although double-stranded AAV genomes probably remain extrachromosomal in mouse myofibers, their tight association with chromatin allows their persistence and stable expression over periods of several months. [15] [16] [17] This particular feature of AAV vectors might be advanta- Antiatherogenic effect of AAV-mediated IL-10 gene transfer T Yoshioka et al geous in investigating the effects of transgenes on chronic disease processes. Previous reports demonstrated that there was a significant difference in transgene expression by various AAV serotypes transduced into rodent muscle. [18] [19] [20] The AAV1 and AAV5 serotypes were shown to produce 100-to 1000-fold higher serum levels of transgene products, as compared to the AAV2. We selected AAV5 for use in in vivo experiments, since we also observed that gene transfer with AAV5 promoted a much higher level of expression of IL-10, as compared to AAV2-mediated transfer (Figure 2 ). However, AAV1 is reported to more efficiently transduce muscle than AAV5. Therefore, we anticipate that the use of AAV1 in future experiments would allow for a minimized vector dosage.
We focused on the effect of IL-10 on in vivo MCP-1 expression. MCP-1, one of the most studied members of the C-C family of chemokines, is expressed in several cell types in the arterial wall, including vascular endothelial cells, smooth muscle cells, and monocytes/ macrophages, under numerous inflammatory conditions. Therefore, MCP-1 is thought to play an important role in the ongoing recruitment of monocyte-macrophages into developing lesions in vivo. 21 Previously, we 22 and others 21, 23 reported enhanced MCP-1 expression in experimental and human atherosclerotic lesions. A role for MCP-1 in the initiation of atherogenesis was demonstrated by knockout mice in which the MCP-1 gene itself or its receptor CCR2 was inactivated. 24, 25 In our study, we demonstrated that serum MCP-1 concentrations are significantly lower in IL-10-transduced mice than in control mice. In addition, we observed enhanced MCP-1 expression in the vascular wall of ApoE-deficient mice, as reported previously, 26 which was significantly inhibited by IL-10 gene transfer. Moreover, the extent of atherosclerotic lesion formation was significantly decreased in AAV5-mIL10-transduced mice, and positively correlated with serum MCP-1 concentration. These results suggest that the observed antiatherogenic effect of IL-10 is partly mediated by the inhibition of systemic and local MCP-1 expression.
We also investigated the effect of IL-10 on serum cholesterol levels. Nonlinear regression of serum cholesterol levels relative to serum IL-10 levels revealed a close correlation to a dose-effect model with an EC 50 (5.3 ng/ ml). It is well known that high cholesterol levels lead to atherogenesis in both humans and mice. Atherosclerotic lesion surface area also correlated with the serum cholesterol concentration in our study. van Exel et al 12 recently found a negative correlation between a low IL-10 production capacity of whole blood and total cholesterol level in humans. They speculated that high levels of IL-10 counteract the effects of TNF-a and IL-6 on lipid metabolism. This clinical observation corresponds well with our observation that the serum IL-10 concentration negatively correlates with the reduction in serum cholesterol.
Pinderski et al 8 found that IL-10-transgenic mice showed a decrease in atherosclerotic lesions compared to control mice. However, they found no difference in plasma cholesterol levels between the transgenic and control mice. On the other hand, Von Der Thusen et al 13 showed that prolonged hepatic expression of IL-10 could be achieved following intravenous adenovirus-mediated IL-10 gene transfer to LDL receptor-deficient mice. Administration of IL-10 resulted in reductions in atherosclerotic lumen stenosis and of serum cholesterol, although the cholesterol-lowering mechanism was not clarified. We analyzed the intracellular cholesterol level of HepG2 cells cultured with acetic acid, a cholesterol substrate, in the absence of lipoprotein. This assay can measure de novo cholesterol synthesis, but not cholesterol uptake, in these cells. We also used fluvastatin at a dose of 10 À5 mol/l to inhibit de novo cholesterol synthesis almost completely. 27 The results of these experiments suggested that IL-10, like fluvastatin, significantly inhibits the hepatic production of cholesterol. It was reported that TNF-a and IL-1 increase the levels of HMG-CoA reductase mRNA without affecting the levels of LDL receptor mRNA. 28 In other words, the increase in serum cholesterol levels observed after TNF-a and IL-1 administration is caused by an increase in hepatic cholesterol synthesis rather than a decrease in the We evaluated the expression of HMG-CoA reductase using quantitative PCR. As is expected, IL-10 modulated HMG-CoA reductase expression, whereas fluvastatin did not. These data suggest that the use of IL-10 in combination with statin may improve cholesterol-lowering effects and benefit the patients with atherosclerotic diseases. Finally, we evaluated whether the downregulation of the MCP-1 was affected by the cholesterol-lowering effects of IL-10 or not. Stepwise regression analysis revealed that not only serum cholesterol but also MCP-1 concentration might be significant independent predictors of atherosclerotic lesion area. Therefore, we speculated that anti-inflammatory effect of IL-10 plays an important role in anti-atherogenic effect as well as its cholesterol-lowering effects.
In summary, AAV5-mediated IL-10-gene transfer into the skeletal muscle could introduce efficient and stable IL-10 expression, resulting in a significant antiatherogenic effects in ApoE-deficient mice. It was suggested that this effect was mediated through the anti-inflammatory and cholesterol-lowering effects of IL-10. These results indicate the presence of complex interactions between inflammation and lipid metabolism, as well as the effectiveness of anticytokine therapy using IL-10 in the treatment of atherosclerotic disease.
Materials and methods
Production of AAV vectors
Two recombinant AAV serotypes, type 2 and type 5, were used in these experiments. AAV2 and AAV5 expressing the Escherichia coli b-galactosidase gene under the control of the cytomegalovirus promoter (AAV2-LacZ and AAV5-LacZ) were generated with the proviral plasmids pAAV-LacZ and pAAV5-RNL, respectively. To create AAV2 and AAV5 derivatives expressing murine IL-10 (AAV2-mIL10 and AAV5-mIL10), murine IL-10 cDNA (RIKEN DNA Bank, RDB-1476) was cloned into the BamHI site of pCMV to form pCMVmIL10. The IL-10 expression cassette in pCMVmIL10 was ligated as a NotI fragment to NotI-digested pAAV-LacZ and pAAV5-RNL to form the proviral plasmids pAAV2-mIL10 and pAAV5-mIL10, respectively.
AAV viral stocks were prepared according to the previously described three-plasmid transfection adenovirus-free protocol. 29 Briefly, 60% confluent 293 cells were cotransfected with the proviral plasmid, an AAV helper plasmid (pHLP19 30 for AAV2 or pAAV5RepCap 31 for AAV5), and the adenoviral helper plasmid pAdeno. The crude viral lysate was purified by two rounds of CsCl two-tier centrifugation. 32 The viral stock was titered by dot-blot hybridization with plasmid standards.
pAAV5-RNL and pAAV5-RepCap (identical to 5Re-pCapB) were kindly provided by Dr JA Chiorini, and pAAV-LacZ, pHLP19 and pAdeno were obtained from Avigen, Inc. (Alameda, CA, USA).
In vitro IL-10 gene transfer
The C2C12 cells were cultured in six-well plates with 2 ml Dulbecco's minimal essential medium (DMEM) containing 5% horse serum. At 8 days after plating, differentiated C2C12 cells were transduced with AAV2-mIL10 at various vector doses. The expression of IL-10 was detected by Western blot analysis after immunoprecipitation of conditioned medium and cell lysates. IL-10 concentrations were measured by ELISA (R&D Systems). To investigate the biological activities of IL-10, cultured medium from transduced C2C12 cells was added to cultured J774 cells for 30 min (final IL-10 concentration, 10 ng/ml). J774 cells were then treated with 100 ng/ml LPS and incubated for an additional 24 h. The supernatants were harvested and the concentrations of IL-6, TNF-a, and MCP-1 were quantified by ELISA (R&D Systems).
In vivo IL-10 gene transfer
All animal experiments were performed in accordance with the Jichi Medical School Guide for Laboratory Animals, 1993. Male ApoE-deficient mice in the C57BL/6J background (a kind gift of Dr N Maeda 33, 34 ) were fed on a Western-type diet containing 21% fat and 0.15% cholesterol (Harlan Teklad) from 8 weeks of age. Water and food were given ad libitum, and the mice were maintained on a 12-h light-dark cycle. At 8 weeks of age, ApoE-deficient mice were injected with AAV2-mIL10 (1 Â 10 13 genome copies/body), AAV5-mIL10 (1 Â 10 11 -10 13 genome copies/body), or AAV5-LacZ (1 Â 10 13 genome copies/body) as 50 ml in total into two distinct sites of the anterior tibial muscle. The serum concentrations of IL-10 and MCP-1 were measured by ELISA as described above. The serum concentrations of total cholesterol were measured by HDAOS methods (Wako Pure Chemicals).
Morphometric analysis
At 8 weeks after the AAV5-mIL10 or -LacZ inoculation, the ascending aortas were removed after perfusion fixation with 4% paraformaldehyde at physiological pressure, embedded in OCT compound (Tissue-Tek), and frozen in liquid nitrogen. Atherosclerotic lesions in the aortic sinus were examined at five locations separated by 80 mm, with the most proximal site at the point where the aortic valves first appeared, and were stained with oil red-O. To quantify the aortic lesions, each image was digitized and analyzed under a microscope (Olympus) with National Institutes of Health Image software (ver. 1.61). Oil red-O-positive areas were analyzed in comparison with the total cross-sectional vessel wall area. The average value for five locations in each animal was determined.
Immunohistochemical analysis
Arterial sections were prepared from 8-week-old mice transduced with AAV5-IL-10 or AAV5-LacZ at 4 weeks old. These sections were incubated with a primary goat polyclonal antibody against mouse MCP-1 (dilution 1/250, Santa Cruz Biotechnology). Nonspecific IgG was used as a negative control. Sections were incubated with biotinylated anti-mouse secondary antibody and treated with peroxidase-conjugated streptavidin, with 3 0 , 3 0 -diaminobenzidine tetrahydrochloride as the enzyme substrate, and counterstained with hematoxylin.
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Measurement of cellular cholesterol
HepG2 cells (human hepatocytes) were maintained in a 12-well plate with 1 ml of MEM containing 10% fetal bovine serum, 1% nonessential amino acids (NEAA; ICN), and 1 mmol/l sodium pyruvate at 371C in a 5% CO 2 incubator for 5 days. The medium was then replaced with 1 ml of MEM containing 10% lipoprotein-deficient serum (LPDS; ICN), 1% NEAA, and 1 mmol/l sodium pyruvate. After 2 days later, the cells were incubated with 1 ml of MEM containing 10% LPDS, 1% NEAA and 1 mmol/l sodium pyruvate, and various concentrations (0-100 ng/ml) of recombinant human IL-10 (PeproTech) or 10 À5 mol/l fluvastatin (Tanabe) were added to the culture. At 2 days after the treatment, the cells were incubated with 0.5 ml of MEM containing 10% LPDS, 1% NEAA, 1 mmol/l sodium pyruvate, and 2 mmol/l acetic acid for 16 h. The cellular cholesterol level was measured by an enzymatic method using Determiner TC-555 (Kyowa Medics).
mRNA analysis of HMG-CoA reductase
HepG2 cells were incubated with either recombinant human IL-10 (10 ng/ml) or fluvastatin (10 À5 mol/l) in 10% LPDS medium for 24 h. Total RNA was isolated from the cell culture using an RNeasy Mini kit (QIAGEN) and reverse-transcribed into a singlestranded cDNA using SuperScript Preamplification System (GIBCO BRL). To estimate the expression of HMG-CoA reductase in HepG2, quantitative PCR analysis was conducted by using ABI PRISM 7700 Sequence Detection System (Applied Biosystems). The reaction was performed using the primer pairs specific for the HMG-CoA reductase (HMGCR-5 0 : GGCCCA GTTGTGCGTCTTCC and HMGCR-3 0 : GTTTGCTGC ATGGGCGTTGTAG) and GAPDH (GAPDH-5 0 : CGCG GGGCTCTCCAGAACATCAT and GAPDH-3 0 : CCAGCC CCAGCGTCAAAGGTG). Quantitative values were obtained from the threshold cycle (C t ) number that indicated exponential amplification of the PCR product. To normalize each sample, we also quantified the expression of the GAPDH gene. The relative target gene expression was also normalized with a calibrator (HepG2 cells without treatment of IL-10 or fluvastatin). The final result, expressed as N-fold differences in target gene expression relative to the GAPDH gene and the calibrator, was determined by the following formula: N target ¼ 2 correctedDCt ðGAPDHÀtarget geneÞ . C t values of the sample were determined by subtracting the average C t value of the target gene from the average C t value of the GAPDH gene.
Statistical analysis
Student's t-test or ANOVA combined with Scheffe's test was used to compare individual groups, and the Pearson's correlation test was employed to measure the linear association between two variables by using StatView (Abacus Concepts, Inc). Data are presented as means7s.e.m. A value of Po0.05 was considered significant.
